Preeclampsia is a leading cause of maternal death and a major contributor to maternal and perinatal morbidity. The molecular basis for the pathogenesis of preeclampsia is poorly understood. However, significant insight has been provided by recent evidence indicating that women with preeclampsia have autoantibodies capable of activating the angiotensin receptor AT1. These AT1 receptor agonistic autoantibodies, termed AT1-AAs, may account for many features of preeclampsia. The following specific aims are designed to evaluate the functional importance of AT1-AAs in the pathophysiology of preeclampsia, the potential of autoantibody blocking therapies for the treatment of preeclampsia and the mechanism by which these autoantibodies activate the AT1 receptor. Associated with each aim is a list of specific questions to be addressed.
AIM I. Evaluate the potential contribution of AT1-AAs to the pathophysiology of preeclampsia. A. How do AT1-AAs contribute to the maternal syndrome? B. Do AT1-AAs contribute to the placental abnormalities associated with preeclampsia? C. Do AT1-AAs contribute to fetal growth retardation? D. What pathophysiological consequences of AT1-AAs are independent of pregnancy? AIM II. Examine therapeutic strategies based on blocking autoantibody-induced AT1 receptor activation. A. What epitope peptides are most effective at blocking autoantibody-induced AT1 receptor activation? B. How effective are therapeutic strategies based on the use of antibody blocking epitope peptides? C. Can autoantibody-induced features of preeclampsia be reversed by antibody blocking epitope peptides? AIM III. Determine the mechanism of autoantibody-induced AT1 receptor activation. A. Is AT1 receptor activation the result of AT1-AA-induced AT1 receptor homodimerization? B. Does antibody binding result in prolonged AT1 receptor activation? C. Do AT1-AAs contribute to AT1 receptor heterodimerization with the bradykinin B2 receptor? If AT1-AAs play a major role in the pathophysiology of preeclampsia, as we hypothesize, it should be possible to block this antibody response and in this way either forestall or prevent the onset of this disease. Our research is likely to contribute significantly to these goals. Preeclampsia is a serious hypertensive condition of pregnancy that is a leading cause of maternal and neonatal mortality and morbidity in the United States and the world. Research proposed here tests the hypothesis that autoantibodies present in women with preeclampsia contribute to many features of the condition.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Research Project (R01)
Project #
Application #
Study Section
Pregnancy and Neonatology Study Section (PN)
Program Officer
Ilekis, John V
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center Houston
Schools of Medicine
United States
Zip Code
Liu, Chen; Wang, Wei; Parchim, Nicholas et al. (2014) Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification. Hypertension 63:353-61
Wang, Wei; Parchim, Nicholas F; Iriyama, Takayuki et al. (2014) Excess LIGHT contributes to placental impairment, increased secretion of vasoactive factors, hypertension, and proteinuria in preeclampsia. Hypertension 63:595-606
Xia, Yang; Kellems, Rodney E (2013) Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res 113:78-87
Siddiqui, Athar H; Irani, Roxanna A; Zhang, Weiru et al. (2013) Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1 induction contributes to impaired adrenal vasculature and decreased aldosterone production in preeclampsia. Hypertension 61:472-9
Siddiqui, Athar H; Irani, Roxanna A; Zhang, Yujin et al. (2011) Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice. Am J Hypertens 24:606-12
Xia, Yang; Kellems, Rodney E (2011) Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 7:659-74
Zhou, Cissy Chenyi; Irani, Roxanna A; Dai, Yingbo et al. (2011) Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J Immunol 186:6024-34
Zhou, Cissy Chenyi; Irani, Roxanna A; Zhang, Yujin et al. (2010) Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation 121:436-44
Siddiqui, Athar H; Irani, Roxanna A; Blackwell, Sean C et al. (2010) Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 55:386-93
Zhou, Cissy Chenyi; Ahmad, Shakil; Mi, Tiejuan et al. (2008) Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 51:1010-9

Showing the most recent 10 out of 26 publications